Editorial: Circadian rhythms and cancer hallmarks: toward advances in immune-based therapeutics, and outcomes

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 28, 2025

Circadian rhythms are the daily fluctuaBons in physiological processes that govern cell cycles and Bming of behaviors (1). Cancer hallmarks cellular properBes drive perennial growth, survival spread cancerous cells (2). The disrupBon circadian can contribute to development some cancers by affecBng expression cancer (3). also temporally regulate immunity, which has important implicaBons for burgeoning field immune-based therapeuBcs (4). paBents exhibiBng disrupted tend suffer accelerated tumor growth metastasis, worse anB-cancer treatment outcomes, poorer health-related quality life overall (5). aim this special issue is help elucidate impact on associated with its treatments, immunotherapy parBcular. We were pleased accept eleven original manuscripts research topic.Through various approaches, several groups explored molecular underpinnings connecBon between clock cancer. Pan colleagues have extensively reviewed role E-box-binding transcripBon factors physiology biology, as well their potenBal novel therapeuBc targets. broad group include two core genes, BMAL-1 CLOCK. With a outlook, work advances our knowledge targets treatment. Zheng focus latest evidence implicaBng rhythm causal factor endometrial further explore mediaBon these effects non-coding RNAs. New irregular circadian-linked ncRNAs described, may future targeted strategies. Meng deployed Mendelian randomizaBon analyBcal approach large internaBonal databases 5 geneBcally independent features colorectal risk. Strikingly, they observed an individual chronotype might significantly lifeBme risk developing Peng offer mulB-gene prognosBc model developed using genes demonstrated predicBve performance gynecologic prognosis. This bioinformaBcs -validated human data -also provides insights into elucidaBng immune signaling pathways high-risk gene profiles.Several criBqued or provided importance sleep influences outcomes. Gouldthorpe colleagues, reviewing studies incorporate objecBve measurement, provide useful compendium diverse indices used summarize endocrine data, acBgraphy sleep-wake cycles, urgent call standardizaBon measurement. need highlighted Jagielo who find both corBsol dysregulaBon abnormal rest-acBvity clearly linked psychological comorbidiBes advanced paBents, such pain, faBgue, nausea, vomiBng, cachexia. Promising chronomodulated chemotherapy circadian-targeBng behavioral intervenBons discussed.Nehnin highlight new promising regulated funcBon gliomas, poinBng targeBng regulaBon microenvironment, disBnct pediatric cancers. Burch associaBon formally diagnosed disorders occurrence robust sample Veterans. They idenBfy opBmal duraBon protecBon against oncogenesis: elevated was noted among those slept average less than 6, more 8, hours nightly. InteresBngly, greater severity longer displayed incidence. Finally, Cash report pilot opens avenues exploraBon links diurnal expression, head neck progression, inflammaBon. emphasize mulB-day sampling. Together, suggest recognizing relaBon levels, clinicians could opBmize schedules align paBents' rhythms, potenBally enhancing outcomes.Through unique mechanism acBon, checkpoint inhibitors influenced host physiology, including rhythms. Two mini reviews growing interacBons inhibitors. In first, Hughes criBcally revised how light exposure, physical exercise diet, notably respecBve Bmings across 24 hours, efficacy Balachandran review emerging suggesBng disturbance inversely correlated responsiveness immunotherapy. Nascent microbiome considered along remaining unanswered quesBons, whether interconnecBons be exploited improve paBent response These lay foundaBons circadian-based lifestyle modificaBons implemented manipulate maximize benefit from (6).This highlights outcomes perspecBves: (cancer paBent) microenvironment. perspecBves quesBons. To we must establish mechanisms acquisiBon hallmarks. line inquiry lead pharmacotherapeuBc increase efficacy.Research tumors, tumors disrupt rhythmicity within microenvironments. Host rarely studied same organism. Such will inform bidirecBonal host--tumor relaBonships: e.g., do suppress promote own genes? Research imperaBves establishing temporal precedence cancer, exist tumor, malignant nonmalignant clinical groups. StandardizaBon protocols assessing popular measures (e.g., corBsol, melatonin) needed addiBon pursuing lesserstudied body temperature, pupillometry, blood pressure dipping). A area ripe regards immunotherapy). should leverage biorepositories epidemiological-level data. Despite research, clear healthcare providers assess treat paBents. While technologies measuring, example, promising, many remain burdensome There remains translaBon measurement senngs individualized intervenBons.

Language: Английский

Bibliometric and visual analysis of drug-specific immunotherapy from 1990 to 2024

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Specific immunotherapy (SIT) is key in allergic diseases, tumor immunity, and autoimmune regulation. In recent years, the mechanism of action drugs SIT has attracted much attention, including induction hypersensitivity responses modulation immune tolerance. However, scientific challenges remain regarding their optimization strategies. Studies on pharmacological have been accumulated past, there an urgent need for bibliometric analyses to review prospect these results future academic development. Strict search criteria were developed screen download literature information from Web Science Core Collection. Six elements included analyzed visualized using Citespace, VOSviewer software, Bibliometrix package. A total 682 publications related drug this study. The growth trend number evident entering a new phase with great potential future, highest citations 1998. countries institutions most USA University Genoa. author who contributed field was Incorvaia, Cristoforo. Moreover, Bousquet J influential author. Allergy considered leading core source journal, Journal Clinical Immunology influential. reference outbreak intensity Roberts G, 2018, Allergy, V73, P765, https://doi.org/10.1111/all.13317 . analysis keywords by various metrics shows that research hotspot tumor-associated SIT, cutting-edge topic AIT, respiratory application hot issue. Drug made good progress joint participation global institutions, scientists, journals. cooperation communication are weak, it necessary build mode promote globalization results. We found hotspots issues field, which will guide us make breakthroughs more precise direction play important role safety safeguarding human life health.

Language: Английский